100 likes | 149 Views
Oncolytic virus therapy is based on the treatment through a virus that infects and kills cancer cells. These oncolytic viruses not only destroy the cancerous cell, also prevents the growth of tumour cells by stimulating the host anti-tumour immune responses. The first oncolytic virus therapy was approved in 2015, it is still is in the nascent stage of being considered as suitable and effective cancer therapy. The first oncolytic virus was the genetically modified herpes simplex virus type I that is Talimogene laherparepvec (T-VEC) that reported to be clinically beneficial for patients with melanoma.
E N D
Orion Market Research Global Oncolytic Virus Therapy Market Research and Forecast, 2018-2023 Global oncolytic virus therapy market size, share, market intelligence, company profiles, market trends, growth, strategy, research report, analysis, overview, forecast 2018-2023
DEFINITION Oncolytic virus therapy is based on the treatment through a virus that infects and kills cancer cells. These oncolytic viruses not only destroy the cancerous cell, also prevents the growth of tumour cells by stimulating the host anti-tumour immune responses.
MARKET MOTIVATORS • Increasing prevalence of melanoma cancer • Negative effects associated with conventional treatments such as chemotherapy • Growing investments in oncolytic virus R&D
MARKET SEGMENTATION BY PRODUCT • HSV-Based oncolytic viruses • Adenoviruses-based oncolytic viruses • Vaccinia virus-based oncolytic viruses • Vesicular stomatitis virus-based oncolytic viruses • Newcastle disease virus-based oncolytic viruses
MARKET PLAYERS • Amgen Inc. • F. Hoffmann-La Roche Ltd. • Merck KGaA • Takara Bio, Inc. • Transgene SA
FOR MORE DETAILS PLEASE VISIT OUR WEBSITE Orion Market Research Pvt. Ltd. (OMR Global) 116, Shagun Arcade, Vijay Nagar Square, Indore, Madhya Pradesh India- 452010 +91-7803040404 +1-6467557667 info@omrglobal.com www.omrglobal.com https://www.omrglobal.com/industry-reports/oncolytic-virus-therapy-market/